

Localisation of transforming growth factor β_1 and β_3 mRNA transcripts in normal and fibrotic human lung

R K Coker, G J Laurent, P K Jeffery, R M du Bois, C M Black, R J McAnulty

Abstract

Background—Transforming growth factor β_1 is implicated in the pathogenesis of lung fibrosis. It promotes extracellular matrix accumulation by increasing procollagen synthesis and reducing degradation. TGF β_1 gene and protein expression increase in experimental lung fibrosis, and TGF β_1 antibodies attenuate fibrosis in mice. The role of other TGF β isoforms is unclear. This study aimed to localise TGF β_1 and TGF β_3 gene expression in fibrotic human lung and compare it with that in normal human lung.

Methods—Lung tissue from patients with cryptogenic fibrosing alveolitis and fibrosis associated with systemic sclerosis was examined by in situ hybridisation. Macroscopically normal lung from carcinoma resections was used as control tissue. Digoxigenin labelled riboprobes were synthesised from TGF β isoform specific cDNA templates.

Results—The digoxigenin labelled riboprobes were sensitive and permitted precise cellular localisation of mRNA transcripts. TGF β_1 and TGF β_3 mRNA transcripts were widespread in normal lung and localised to alveolar macrophages and bronchiolar epithelium. TGF β_1 but not TGF β_3 mRNA was detected in mesenchymal and endothelial cells. In fibrotic lung tissue mRNA transcripts for both isoforms were also detected in metaplastic type II cells. TGF β_1 gene expression was enhanced in some patients. TGF β_3 was expressed in fibrotic lung but was not consistently altered compared with controls.

Conclusion—TGF β_1 mRNA transcripts were localised in normal and fibrotic human lung and TGF β_3 gene expression in human lung fibrosis was shown for the first time. The results suggest that TGF β_1 may play the predominant role in pathogenesis. It is suggested that TGF β_1 should be the primary target of anticytokine treatments for pulmonary fibrosis.

(Thorax 2001;56:549–556)

Keywords: pulmonary fibrosis; transforming growth factor β ; gene expression

extracellular matrix including collagen.¹ The transforming growth factor beta (TGF β) family has been implicated in the pathogenesis. TGF β_1 is a potent promoter of extracellular matrix deposition and acts by increasing production as well as reducing degradation.² TGF β_1 gene expression and protein synthesis increase in experimental^{3,4} and human pulmonary fibrosis.^{5,6} Enhanced pulmonary expression of active TGF β_1 induces a chronic fibrotic response,⁷ while serum TGF β_1 levels predict pneumonitis and lung fibrosis in patients undergoing radiotherapy.^{8,9} Furthermore, the homozygous TGF β_1 genotype, which correlates with excessive TGF β_1 expression, is a risk factor for allograft lung fibrosis.¹⁰

The role of the other mammalian TGF β isoforms, TGF β_2 and TGF β_3 , remains unclear. We have previously shown that all three isoforms stimulate synthesis of human fibroblast procollagen and reduce intracellular degradation in vitro. We have also demonstrated differential TGF β isoform gene expression in murine bleomycin induced lung fibrosis.¹¹ The data suggest that, unlike TGF β_1 , TGF β_3 is not involved in the pathogenesis. Finally, we have shown that TGF β_1 and TGF β_3 mRNA transcripts are widespread in normal murine and human lung.¹² The aims of this present study were to determine whether TGF β_3 is expressed in fibrotic human lung and to compare the localisation of TGF β_1 and TGF β_3 mRNA transcripts in fibrotic human lung with that in normal human lung.

Methods

TISSUE PREPARATION

Lung tissue was obtained from open lung biopsy specimens of eight patients with pulmonary fibrosis, five from patients with pulmonary fibrosis associated with systemic sclerosis (SSc) and three from patients with cryptogenic fibrosing alveolitis (CFA). Patients with CFA were diagnosed following history and examination, investigations including high resolution computed tomography and pulmonary function testing, and exclusion of other risk factors for pulmonary fibrosis such as dust exposure or connective tissue disease. All patients with SSc fulfilled the American Rheumatism Association preliminary criteria for the diagnosis of systemic sclerosis. No patients were receiving treatment for lung disease at the time of investigation or biopsy. Macroscopically normal lung from two patients undergoing resection for lung cancer was used as a control. Only macroscopically and histologically normal peripheral lung was chosen for these studies.

Centre for
Cardiopulmonary
Biochemistry &
Respiratory Medicine,
Royal Free &
University College
Medical School,
University College
London, Rayne
Institute, London
WC1E 6JJ, UK
R K Coker
G J Laurent
R J McAnulty

Respiratory Medicine,
Royal Brompton
National Heart & Lung
Hospital, London
SW3 6LY, UK
P K Jeffery
R M du Bois

Department of
Rheumatology, Royal
Free Hospital, London
NW3 2QG, UK
C M Black

Correspondence to:
Dr R K Coker, Department
of Respiratory Medicine,
Hammersmith Hospital, Du
Cane Road, London W12
OHS, UK
robina.coker@ic.ac.uk

Received 15 September 2000
Returned to authors
20 November 2000
Revised version received
29 January 2001
Accepted for publication
26 February 2001

The pathogenesis of pulmonary fibrosis is not yet fully elucidated but one current hypothesis is that cytokines released by resident cells and inflammatory cells entering the lung stimulate fibroblasts to synthesise excessive amounts of

Viable tissue was fixed in freshly prepared 4% paraformaldehyde in phosphate buffered saline (PBS). After 4 hours immersion in fixative, lung tissue was transferred to 15% sucrose in PBS prior to dehydration and embedding in paraffin wax.

Prehybridisation treatments were performed using techniques described previously.¹² Briefly, 5 µm sections were cut and placed on slides previously coated with a 2% v/v solution of 3-aminopropyltriethoxysilane in acetone. After dewaxing, sections were rehydrated through a series of ethanol washes of decreasing concentration followed by immersion in 0.14 mol/l sodium chloride and PBS before refixing in freshly prepared 4% paraformaldehyde. In order to maximise probe penetration into cells, sections were treated with proteinase K (Life Technologies, Paisley, UK) at a concentration of 20 µg/ml in 50 mmol/l Tris hydrochloride, pH 7.5, 5 mmol EDTA for 10 minutes before refixing with paraformaldehyde. Sections were then acetylated by immersion in freshly prepared 0.1 mol/l triethanolamine containing 0.25% acetic anhydride and subsequently dehydrated through a series of increasing concentrations of ethanol.

PROBE PREPARATION

Riboprobes were synthesised from transcript specific murine TGFβ cDNA constructs in pGEM vectors. The constructs were obtained by deletion of the highly conserved regions of the two murine cDNAs and the specificity of riboprobes synthesised from these templates is established.^{13 14} The TGFβ₁ construct includes nucleotides 421–1395 of the murine cDNA and contains 764 bp of the amino terminal glycopeptide (precursor) region and 210 bp of the mature region. The TGFβ₃ construct contains 609 bp of the amino terminal glycopeptide region (831–1440). The TGFβ isoforms are well conserved between species at peptide, N-terminal precursor region, and genomic levels.^{15 16}

Digoxigenin labelled riboprobes were synthesised by *in vitro* transcription from the linearised cDNA templates using the appropriate RNA polymerase (SP6 or T7) according to the manufacturer's protocol (Boehringer Mannheim, Lewes, UK).

IN SITU HYBRIDISATION

This protocol was based on previously described methods.^{11 12} Hybridisation buffer consisting of 50% deionised formamide, 300 mmol/l NaCl, 20 mmol/l Tris HCl (pH 7.4), 5 mmol/l EDTA, 10 mmol monosodium phosphate (pH 8.0), 10% dextran sulphate, 1 × Denhardt's solution, and 500 µg/ml yeast tRNA was mixed with the digoxigenin labelled probe at a ratio of 9:1 to give a final probe concentration of 20 ng/ml. A 25 µl aliquot of hybridisation solution was applied to each slide and sections were incubated overnight (16 hours) at 50°C in a sealed chamber humidified with a solution of 50% formamide in 2 × saline sodium citrate (SSC). After hybridisation, all incubations were performed at room temperature. Slides were washed in 4 × SSC for 30

minutes, then in 0.2 × SSC for 30 minutes, and finally in Tris buffered saline (TBS, consisting of 0.1 mol/l Tris, pH 8.2, 0.15 mol/l NaCl) for 5 minutes. They were then incubated for 30 minutes with antibody blocking solution consisting of 5% bovine serum albumin and 5% normal sheep serum diluted in TBS with 0.1% Tween 20 (Sigma, Dorset, UK). After two additional 5 minute washes in TBS, the slides were incubated with antibody solution for 30 minutes. This consisted of a 1:100 dilution of anti-digoxigenin-alkaline phosphatase Fab fragments (Boehringer Mannheim) in 1% bovine serum albumin in TBS with Tween 20. Sections were then washed twice in TBS for 5 minutes each.

For detection of bound antibody, sections were incubated with alkaline phosphatase substrate New Fuschin Red (Dako, High Wycombe, UK). This was prepared according to the manufacturer's instructions and 1 mmol/l levamisole was added to inhibit endogenous alkaline phosphatase activity.¹⁷ A 200 µl aliquot of freshly prepared reagent was applied to each section for 20 minutes. The slides were then rinsed in distilled water and counterstained with haematoxylin or methyl green. New Fuschin Red yields a red colour at the site of hybridised probe. Each *in situ* experiment was repeated at least once.

Sections were examined and reported independently by three of the authors (RKC, PKJ, RJM). Control and fibrotic sections were tested in the same hybridisation run. The cell types expressing TGFβ were compared and the intensity of signal rated on a scale of mild (+), moderate (++) or intense (+++). Expression in fibrotic lung was compared with expression in control sections. The slides were blinded and the results discussed. Where agreement could not be reached as to whether signal was increased, unchanged or decreased, these slides were excluded from the analysis.

Results

PATIENT CHARACTERISTICS

Control sections were analysed from two patients, a woman aged 59 years with bronchial adenocarcinoma and a man aged 44 years with mixed small cell carcinoma and adenocarcinoma. Both were smokers. Fibrotic specimens were examined from five patients with SSc and three with CFA. The patients with SSc were women ranging in age from 36 to 55. Two of the patients with CFA were men aged 64 and 66 and the third was a woman aged 42. Three patients with SSc had a predominantly cellular pattern and two had a predominantly fibrotic pattern of disease. Two patients with CFA had advanced fibrosis and one had patchy fibrosis.

TGFβ ISOFORM EXPRESSION IN NORMAL HUMAN LUNG

As reported previously,¹² TGFβ₁ and TGFβ₃ mRNA transcripts were widespread in normal human lung and localised predominantly to alveolar macrophages and bronchiolar epithelium. Figure 1a, c, and d illustrate the typical cellular localisation of TGFβ₁ gene expression




Figure 1 *In situ* hybridisation in normal human lung with $TGF\beta_1$ and $TGF\beta_3$ riboprobes. Hybridisation signal for $TGF\beta_1$ was evident in bronchial epithelium (a), alveolar macrophages (arrows in c), alveolar walls (arrowheads in c), and mesenchymal cells (d). $TGF\beta_3$ mRNA transcripts were localised to alveolar macrophages (e and g) and bronchial epithelium (h). No hybridisation signal was obtained with $TGF\beta_1$ or $TGF\beta_3$ sense riboprobes (b and f, respectively). Counterstain in a, b, d, e, and g: methyl green. Internal scale bar = 50 μ m; original magnification variable from $\times 200$ to $\times 1000$.

in normal human lung; $TGF\beta_1$ mRNA transcripts were localised to bronchial epithelium (arrows in fig 1a), alveolar macrophages (arrows in fig 1c), alveolar walls (arrowheads in

fig 1c), and mesenchymal cells (arrows in fig 1d). Figure 1e, g, and h illustrate the typical cellular localisation of $TGF\beta_3$ gene expression in normal human lung; $TGF\beta_3$ mRNA




Figure 2 *In situ* hybridisation in fibrotic human lung with $TGF\beta_1$ and $TGF\beta_2$ riboprobes. $TGF\beta_1$ mRNA transcripts were localised to inflammatory cells (a) and bronchial epithelium (b) in a patient with SSC, and to alveolar macrophages in a patient with CFA (c). $TGF\beta_1$ mRNA transcripts were also localised to type I alveolar epithelial cells (d) and mesothelial cells (e) in a patient with SSC. $TGF\beta_2$ mRNA transcripts were localised to inflammatory cells (h), bronchial epithelium (i) and mesothelial cells (j) in a patient with SSC. Hybridisation signal for $TGF\beta_2$ was also noted in intra-alveolar macrophages (arrowheads in k) and in cuboidal type I alveolar epithelial cells lining the alveolar surface (arrows in k). This lung tissue was taken from a patient with SSC. No hybridisation signal was obtained with $TGF\beta_1$ or $TGF\beta_2$ sense riboprobes (f and g, respectively). Counterstain: methyl green. Internal scale bar = 50 μ m; original magnification $\times 400$.




Figure 3 Lung tissue from a patient with CFA and advanced fibrosis hybridised with (a) TGF β_1 and (b) TGF β_3 antisense riboprobes showing the absence of TGF β_1 and TGF β_3 gene expression in advanced lung fibrosis. No hybridisation signal for either isoform was detected in sections. Counterstain: methyl green. Internal scale bar = 50 μ m; original magnification \times 400.

transcripts were localised to alveolar macrophages (arrows in fig 1e and g) and bronchial epithelium (arrows in fig 1h). No hybridisation signal for TGF β_1 or TGF β_3 was detected with sense riboprobes (fig 1b and f, respectively). TGF β_1 but not TGF β_3 mRNA transcripts were also detected in pulmonary endothelial cells (data not illustrated).

TGF β ISOFORM EXPRESSION IN FIBROTIC HUMAN LUNG

In fibrotic lung tissue mRNA transcripts for both isoforms were also localised to alveolar macrophages, bronchial epithelial cells, alveolar epithelial cells, and mesothelial cells. TGF β_1 mRNA transcripts were furthermore detected in mesenchymal cells. Gene expression for neither isoform was detected in pulmonary endothelial cells in fibrotic lung tissue. Figure 2 illustrates the typical cellular localisation of TGF β_1 and TGF β_3 gene expression in fibrotic human lung. TGF β_1 mRNA transcripts were localised to areas of inflammatory cell infiltrate (fig 2a) and bronchial epithelium (fig 2b) in a patient with SSc, and to alveolar macrophages in a patient with CFA (fig 2c). TGF β_1 mRNA

Table 1 Cell types expressing TGF β_1 and TGF β_3

Cell type	Controls		Fibrotic patients	
	TGF β_1	TGF β_3	TGF β_1	TGF β_3
Alveolar macrophage	+	+	+	+
Bronchial epithelial	+	+	+	+
Alveolar wall	+	-	+	+
Pulmonary endothelial	+	-	-	-
Mesothelial	+	-	+	+
Mesenchymal	+	-	+	-

There was no difference in localisation between sections from patients with SSc and patients with CFA. + = detected; - = not detected.

Table 2 Quantitative changes in TGF β_1 and TGF β_3 gene expression in fibrotic human lung

Diagnosis	Histology	TGF β_1	TGF β_3
SSc	Cellular	↑	↓
SSc	Fibrotic	↑	→
SSc	Fibrotic	→	→
SSc	Fibrotic	→	-
SSc	Cellular	→	→
CFA	Fibrotic	→	→
CFA	Fibrotic	-	-
CFA	Mixed	↑	↑

TGF β_1 gene expression was increased in three of the eight biopsy specimens while TGF β_3 gene expression was enhanced in only one.

SSc = systemic sclerosis; CFA = cryptogenic fibrosing alveolitis; ↑ = increased gene expression; ↓ = decreased; → = unchanged compared with control human lung tissue; - = not detected.

transcripts were also localised to type I alveolar epithelial cells (fig 2d) and mesothelial cells (fig 2e) in a patient with SSc. TGF β_3 mRNA transcripts were localised to inflammatory cells (fig 2h), bronchial epithelium (fig 2i), and mesothelial cells (fig 2j) in a patient with SSc. Hybridisation signal for TGF β_3 was also noted in intra-alveolar macrophages (arrowheads in fig 2k) and in cuboidal type I alveolar epithelial cells lining the alveolar surface (arrows in fig 2k). This lung tissue was taken from a patient with SSc. No hybridisation signal for TGF β_1 or TGF β_3 was detected using sense riboprobes (panels fig 2f and g, respectively).

Figure 3 illustrates the absence of TGF β_1 and TGF β_3 gene expression in advanced lung fibrosis. Consecutive sections of lung tissue from a patient with CFA and advanced fibrosis were hybridised with the TGF β_1 (fig 3a) and TGF β_3 (fig 3b) antisense riboprobes. No hybridisation signal was detected for either isoform in sections examined from this biopsy specimen.

The cells expressing TGF β_1 and TGF β_3 in normal and fibrotic human lung are summarised in table 1. There was no difference in localisation between pulmonary fibrosis associated with SSc and CFA.

SEMI-QUANTITATIVE ANALYSIS OF CHANGES IN TGF β_1 AND TGF β_3 GENE EXPRESSION IN FIBROTIC HUMAN LUNG

Semi-quantitative changes in TGF β isoform gene expression in patients with CFA and SSc are shown in table 2. TGF β_1 gene expression was increased in three of the eight biopsy specimens while TGF β_3 gene expression was enhanced in only one.

Discussion

TGF β_1 AND TGF β_3 EXPRESSION IN NORMAL LUNG

Few studies to date have examined TGF β gene expression in normal adult human lung. TGF β_1 mRNA transcripts have been localised to alveolar macrophages^{6,18} using isotopic *in situ* hybridisation, and Northern analysis has demonstrated TGF β_1 gene expression in the airways of healthy smokers.¹⁹ We have previously reported both TGF β_1 and TGF β_3 gene expression in adult human lung,¹² the findings of which are confirmed by this present study.

The data presented here show that mRNA transcripts for both TGF β_1 and TGF β_3 are present in normal human lung and predominantly co-localised to bronchiolar epithelium and alveolar macrophages. TGF β gene expression was also observed in pulmonary endothelial and mesenchymal cells. Immunohistochemical studies in normal human lung and healthy smokers have demonstrated TGF β in bronchial epithelium, alveolar macrophages, smooth muscle cells, and blood vessels,^{19,20} but some workers report little or no TGF β_1 in normal lung.^{21,22} The latter study demonstrated TGF β_3 protein in alveolar macrophages, epithelial, and smooth muscle cells in normal human lung. Taken together, these data suggest that, as we have previously shown for murine lung,¹² gene and protein expression for TGF β_1 and TGF β_3 are co-localised, indicating an autocrine as well as paracrine mode of action. As in murine lung, the diversity of cells expressing these genes is consistent with the wide variety of biological functions ascribed to these peptides.

TGF β_1 AND TGF β_3 EXPRESSION IN FIBROTIC LUNG

TGF β_1 gene expression appeared to be increased in three of the eight patients while TGF β_3 gene expression was increased in only one. In patients with dense fibrosis there was a paucity of hybridisation signal for either isoform. These results confirm the findings in murine bleomycin induced lung fibrosis that the isoforms are generally co-localised but that differential gene regulation occurs. Although the numbers of patients are too small for definitive conclusions to be drawn, there was a tendency for TGF β_1 to be the predominant isoform expressed in fibrotic lung. Since TGF β_1 gene and protein expression²³ and serum levels²⁴ are increased in lung cancer, and our control lung tissue was obtained from tumour resections, the increases observed in TGF β_1 and TGF β_3 gene expression may be an underestimate.

Human lung tissue was taken from current or previous smokers, raising the possibility that smoking might alter TGF β gene expression. To date no studies have addressed this question directly. Although nicotine reduces TGF β_1 release by bovine aortic endothelial cells *in vitro*,²⁵ it does not alter TGF β_1 gene expression. A study of TGF β_1 gene expression in human airways showed no differences between smokers and non-smokers.¹⁹

Our findings suggest that TGF β_1 may be more consistently implicated in the pathogenesis of pulmonary fibrosis associated with SSc

or CFA than is TGF β_3 . This is consistent with the findings of Khalil and colleagues²² who reported ubiquitous TGF β_2 and TGF β_3 protein in normal human lung but little TGF β_1 . In contrast, TGF β_1 was widespread in macrophages, epithelial cells, and extracellular matrix in fibrotic lung. TGF β_2 and TGF β_3 deposition was unchanged in fibrotic lung, suggesting that the presence of TGF β is a marker of chronic fibrosis. However, since the profibrotic potential of TGF β_3 *in vitro* is at least equivalent to that of TGF β_2 ,²⁶ and may exceed it,¹¹ the possibility that this isoform does play an important role in some patients, or at a particular stage of the disease, cannot yet be excluded.

Both TGF β_1 and TGF β_3 mRNA transcripts were observed in fibrotic lung and their distribution appeared to be identical, which suggests that gene activation occurs simultaneously. Gene expression for both isoforms was observed in alveolar macrophages, bronchial epithelium, alveolar walls, and mesothelial cells. No differences in localisation of TGF β_1 and TGF β_3 gene expression were detected between patients with CFA or SSc. This reflects the affinity between these conditions in terms of their histology and radiology, and suggests that aspects of their pathogenesis—including their profile of TGF β induction—are similar. Similarly, a study of TGF β_1 protein deposition in fibrotic lung showed no difference between patients with idiopathic pulmonary fibrosis, asbestosis, hypersensitivity, or non-specific pneumonitis.²¹

The prognosis of pulmonary fibrosis associated with SSc is better than for patients with CFA.²⁷ This may in part be because pulmonary fibrosis in SSc is generally detected earlier and in younger patients. However, enhanced TGF β gene and protein expression, while important in the pathogenesis of the disease, may not be the sole determinant of prognosis and other factors may be implicated.

In contrast with our findings in the murine model,¹¹ a switch from predominant TGF β_1 gene expression in bronchial epithelium to predominantly interstitial expression following lung injury was not observed in human fibrotic lung. There are several possible explanations for this. Firstly, the bleomycin model is a model of acute lung injury rather than slowly progressive disease. Changes in localisation of gene expression may therefore be more subtle and less easily detected in the human disease. Secondly, human airway epithelial cells may be subject to a greater degree of activation than those of laboratory mice, leading to higher basal TGF β gene expression. Finally, patients with pulmonary fibrosis often present relatively late. It is therefore possible that an obvious switch does occur early on in the disease but was no longer apparent by the time the biopsy specimens were taken.

A previous study has examined TGF β_1 gene expression in human fibrotic lung.⁶ This study, employing a radiolabelled probe, localised TGF β_1 gene expression to macrophages adjacent to fibrotic foci but did not detect other cells expressing the gene. This supports our previous suggestion that digoxigenin labelled

riboprobes are probably more sensitive tools than radiolabelled probes for detecting cytokine gene expression in lung tissue.

Immunohistochemical studies of TGF β in pulmonary fibrosis have previously localised the protein to fibroblastic foci,⁶ alveolar macrophages, bronchiolar epithelial and hyperplastic alveolar type II cells.^{5, 21} Our data show a similar distribution for TGF β_1 and TGF β_2 mRNA. These data suggest co-localisation of gene and protein expression and therefore a predominantly autocrine and/or paracrine mode of action for TGF β . This is consistent with previously published findings in murine lung.

Hybridisation signal for both TGF β_1 and TGF β_2 was scarce in biopsy specimens characterised by areas of dense acellular fibrosis. This may reflect the fact that the predominant source of TGF β is inflammatory cells so that, when few of these cells are present, little gene expression is observed. This would be consistent with Broekelmann's data showing that mRNA transcripts for TGF β_1 were associated with macrophages while TGF β_2 was associated with areas of extracellular matrix deposition.⁶ It is also consistent with observations by Asakura and colleagues who found that TGF β_1 protein deposition is associated with early rather than late fibrosis in patients with pulmonary adenocarcinoma.²⁸

Another possibility is that TGF β gene expression is downregulated by matrix protein accumulation. TGF β_1 promoter transcription and gene expression by mammary epithelial cells are downregulated when these cells are cultured in contact with extracellular matrix rather than on plastic.²⁹ This phenomenon was not observed with TGF β_2 and no data are available for TGF β_3 . In vivo studies have shown that TGF β_1 and decorin protein deposition are inversely related in patients with lung fibrosis and adenocarcinoma.²⁸ These findings are consistent with the recognised ability of various extracellular matrix components to bind and sometimes inactivate active TGF β , including betaglycan,³⁰ decorin,³¹ and type IV collagen.³² It might also provide a mechanism whereby tissue injury, involving disruption of the interaction between cells and their basement membranes, promotes enhanced TGF β_1 gene expression. If this is the case, absence of TGF β_1 mRNA transcripts in murine lung bronchial epithelial cells following bleomycin presumably reflects injury severe enough to inhibit gene transcription.

Finally, biopsy specimens characterised by dense fibrosis may simply represent an advanced stage of the disease where the stimulus for increased TGF β gene expression is no longer present. If this is the case, a very low level of TGF β gene expression is presumably sufficient to maintain increased extracellular matrix deposition. It is likely that a combination of the above factors accounts for the reduction in TGF β gene expression observed in association with densely fibrotic lung tissue.

In summary, mRNA transcripts for both isoforms are predominantly co-localised in normal lung to bronchiolar epithelium and alveolar macrophages. TGF β_1 gene expression was also observed in pulmonary endothelial and

mesenchymal cells. In fibrotic lung, gene expression for both isoforms was seen in alveolar macrophages, bronchial epithelium, alveolar walls, and mesothelial cells. No differences in localisation of TGF β_1 and TGF β_2 gene expression were detected between patients with CFA or SSc. TGF β_1 gene expression was more consistently enhanced in fibrotic lung than was TGF β_2 gene expression, which suggests that TGF β_1 may be more frequently implicated in the pathogenesis of pulmonary fibrosis. Gene expression for both isoforms was predominantly localised to areas of inflammation and mild fibrosis. Little hybridisation signal was seen in regions of dense acellular fibrosis.

These results confirm our previous reports of the high sensitivity of digoxigenin labelled riboprobes for localisation of cytokine gene expression in lung tissue. Together with previously published immunohistochemical studies they suggest autocrine and paracrine modes of action for TGF β in human lung and support the view that TGF β plays multiple roles in normal human pulmonary homeostasis. As in the murine model of lung fibrosis, our results show that the isoforms can be regulated differentially, but suggest that the two different forms of pulmonary fibrosis behave similarly in terms of TGF β gene expression.

In conclusion, we have reported TGF β_3 gene expression in fibrotic human lung tissue for the first time. In some patients with lung fibrosis TGF β_1 gene expression was enhanced. TGF β_2 was expressed in fibrotic lung but was not consistently altered compared with controls. Future anticytokine treatments for pulmonary fibrosis may need to be directed predominantly against TGF β_1 .

We are grateful for the gift of cDNA probes for TGF β_1 and TGF β_2 from Professor Harold Moses (Nashville, Tennessee, USA). The work was funded by the Wellcome Trust (London, UK).

- 1 Coker RK, Laurent GJ. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. *Thorax* 1997;52:294-6.
- 2 McNulty RJ, Campa JS, Cambrey AD, *et al.* The effect of transforming growth factor β on rates of procollagen synthesis and degradation in vitro. *Biochim Biophys Acta* 1991;1091:231-5.
- 3 Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor β precede bleomycin-induced pulmonary fibrosis in mice. *J Pharmacol Ex Ther* 1988;246:765-71.
- 4 Khalil N, Berezney O, Sporn MB, *et al.* Macrophage production of transforming growth factor β and fibroblast collagen synthesis in chronic pulmonary inflammation. *J Exp Med* 1989;170:727-37.
- 5 Khalil N, O'Connor RN, Unruh HW, *et al.* Increased production and immunohistochemical localisation of transforming growth factor β in idiopathic pulmonary fibrosis. *Am J Respir Cell Mol Biol* 1991;5:155-62.
- 6 Broekelmann TJ, Limper AH, Colby TV, *et al.* Transforming growth factor β_1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. *Proc Natl Acad Sci* 1991;88:6642-6.
- 7 Sime PJ, Xing Z, Graham FL, *et al.* Adenovector-mediated gene transfer of active transforming growth factor β_1 induces prolonged severe fibrosis in rat lung. *J Clin Invest* 1997;100:768-76.
- 8 Anscher MS, Kong FM, Andrews K, *et al.* Plasma transforming growth factor β , as a predictor of radiation pneumonitis. *Int J Radiat Oncol Biol Phys* 1998;41:1029-35.
- 9 Anscher MS, Peters WP, Reisenbichler H, *et al.* Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. *N Engl J Med* 1993;328:1592-8.
- 10 El-Gamel A, Awad M, Sim E, *et al.* Transforming growth factor β_1 and lung allograft fibrosis. *Eur J Cardiothorac Surg* 1998;13:424-30.
- 11 Coker RK, Laurent GJ, Shahzeidi S, *et al.* Transforming growth factors β_1 , β_2 and β_3 stimulate fibroblast procollagen

- production in vitro but are differentially expressed during bleomycin-induced lung fibrosis. *Am J Pathol* 1997;150:981–91.
- 12 Coker RK, Laurent GJ, Shahzeidi S, et al. Diverse cellular TGF β and TGF β_3 gene expression in normal human and murine lung. *Eur Respir J* 1996;9:2501–7.
 - 13 Perket EA, Pelton RW, Meyrick B, et al. Expression of transforming growth factor β mRNAs and proteins in pulmonary vascular remodelling in the sheep air embolisation model of pulmonary hypertension. *Am J Respir Cell Mol Biol* 1994;11:16–24.
 - 14 Pelton RW, Johnson MD, Perket EA, et al. Expression of transforming growth factor β_1 , β_2 and β_3 mRNA and protein in the murine lung. *Am J Respir Cell Mol Biol* 1991;5:522–30.
 - 15 Derynck R, Jarrett JA, Chen EY, et al. The murine transforming growth factor- β precursor. *J Biol Chem* 1986;261:4377–9.
 - 16 Derynck R, Lindquist PB, Lee A, et al. A new type of transforming growth factor- β , TGF- β_3 . *EMBO J* 1988;7:3737–43.
 - 17 Ponder BA, Wilkinson MM. Inhibition of endogenous tissue alkaline phosphatase with the use of alkaline phosphatase conjugates in immunohistochemistry. *J Histochem Cytochem* 1981;29:981–4.
 - 18 Shaw RJ, Benedict SH, Clark RAF, et al. Pathogenesis of pulmonary fibrosis in interstitial lung disease. *Am Rev Respir Dis* 1991;143:167–73.
 - 19 Aubert J, Dalal BI, Baj TR, et al. Transforming growth factor β_1 gene expression in human airways. *Thorax* 1994;49:225–32.
 - 20 Magan A, Frachon I, Rain B, et al. Transforming growth factor β in normal human lung: preferential location in bronchial epithelial cells. *Thorax* 1994;49:789–92.
 - 21 Corrin B, Butcher D, McAnulty RJ, et al. Immunohistochemical localization of transforming growth factor β_1 in the lungs of patients with systemic sclerosis, cryptogenic fibrosing alveolitis and other lung disorders. *Histopathology* 1994;24:145–50.
 - 22 Khalil N, O'Connor RN, Flanders KC, et al. TGF β_1 , but not TGF β_2 or TGF β_3 , is differentially present in epithelial cells of advanced pulmonary fibrosis: an immunohistochemical study. *Am J Respir Cell Mol Biol* 1996;14:131–8.
 - 23 Jakowlew SB, Moody TW, You L, et al. Transforming growth factor β expression in mouse lung carcinogenesis. *Exp Lung Res* 1998;24:579–93.
 - 24 Kong FM, Washington MK, Jirtle RL, et al. Plasma transforming growth factor β , reflects disease status in patients with lung cancer after radiotherapy: a possible tumor marker. *Lung Cancer* 1996;16:47–59.
 - 25 Cucina A, Corvino V, Sapienza P, et al. Nicotine regulates basic fibroblastic growth factor and transforming growth factor β_1 production in endothelial cells. *Biochem Biophys Res Commun* 1999;257:306–12.
 - 26 Eickelberg O, Kohler E, Reichenberger F, et al. Extracellular matrix deposition by primary human lung fibroblasts in response to TGF β_1 and TGF β_3 . *Am J Physiol* 1999;276:L814–24.
 - 27 Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. *Am J Respir Crit Care Med* 1994;149:1583–90.
 - 28 Asakura S, Kato H, Fujino S, et al. Role of transforming growth factor β_1 and decorin in development of pulmonary fibrosis in pulmonary adenocarcinoma. *Hum Pathol* 1999;30:195–8.
 - 29 Streuli CH, Schmidhauser C, Kobrin M, et al. Extracellular matrix regulates expression of the TGF β_1 gene. *J Cell Biol* 1993;120:253–60.
 - 30 Andres JL, Stanley K, Cheifetz S, et al. Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor β . *J Cell Biol* 1989;109:3137–45.
 - 31 Yamaguchi Y, Mann DM, Ruoslahti E. Negative regulation of transforming growth factor β by the proteoglycan decorin. *Nature* 1990;346:281–4.
 - 32 Paralkar VM, Vukicevic S, Reddi AH. Transforming growth factor β type 1 binds to collagen IV of basement membrane matrix: implications for development. *Dev Biol* 1991;143:303–8.

Narrative Based Medicine, An Interdisciplinary Conference

Research, Narrative, and Practice

A two day conference—Monday 3rd and Tuesday 4th September 2001

Homerton College, Cambridge, UK

BMJ Publishing Group

For full details contact: BMA/BMJ Conference Unit, Tavistock Square, London, WC1H 9JP
Tel: +44 (0)20 7383 6819; fax: +44 (0)20 7383 6663; email: clyders@bma.org.uk.

www.quality.bmjpub.com